By Anika Milian, Esq., Co-Founding Partner, B&M Law Group, PLLC · November 12, 2026
Short answer: if your GLP-1 consent form does not mention vision loss, it is out of date and should be updated now. On November 9, the FDA announced a labeling change adding a warning about sudden vision loss to GLP-1 medications. If your clinic dispenses compounded GLP-1s, there is no manufacturer label to carry that warning for you. Your consent form, protocol, and exam notes have to carry it.
If you searched "GLP-1 vision warning consent form," this article is for you. It covers what to change, who should sign off, and how to document it.
What the GLP-1 vision warning means for your consent form
According to CNN and other coverage of the November 9 announcement, the FDA is requiring a new warning on GLP-1 drug labels about NAION, short for nonarteritic anterior ischemic optic neuropathy. In plain words, NAION is sudden vision loss caused by reduced blood flow to the optic nerve, usually in one eye.
Coverage has described the condition as rare. Read the FDA's own notice for the exact wording, the products covered, and any symptoms patients should watch for. Do not rely on news summaries to draft your form.
Why compounded programs cannot lean on the manufacturer label
A branded drug comes with an FDA-approved label. When the FDA changes that label, the manufacturer updates it, and prescribers see the change.
A compounded drug is made by a pharmacy for an individual patient. It is not FDA-approved and has no label of its own. That means no automatic update will reach your patients.
The warning still matters to them. Florida's medical consent law, section 766.103, Florida Statutes, looks at whether the patient was told about the substantial risks and hazards that a reasonable provider would disclose. A newly announced FDA warning on the same drug class is the kind of information a patient or a reviewing board may later say should have been shared.
This is general information. Whether a specific disclosure is legally required in a given case is a question for your attorney and your medical director.
Did anything change in 2026?
Yes. The November 9 FDA labeling announcement is the change. Many clinics built their GLP-1 consent forms in 2024 or 2025 around nausea, gallbladder issues, pancreatitis, and thyroid warnings. Those forms usually say nothing about the eyes.
The day after the announcement, a Florida personal injury firm issued a press release aimed at patients, highlighting the vision risk. Whatever you think of that kind of marketing, it means patients are likely to read about the warning and ask your staff about it. Staff need a consistent, documented answer.
What your clinic needs to update
- Consent form. Add plain-language disclosure of the NAION warning, including that it involves sudden vision loss and that patients should contact their provider right away or seek urgent care if they notice sudden vision changes. Have your medical director approve the wording.
- Screening and intake. Add questions about prior eye conditions, optic nerve problems, and vision changes. Confirm with your medical director which history should trigger a closer look or a referral.
- Good-faith exam notes. The patient evaluation before prescribing should show that vision history was asked about and the warning was discussed. A blank field is worse than a short, accurate note.
- Written protocol. Update your standing protocol so staff know what to do if a patient reports a vision change: who to call, what to tell the patient, and how to document it. Review it against section 458.348 on physician supervision if you use a medical director or supervising physician.
- Existing patients. Decide with your medical director whether current patients receive the updated disclosure and sign a short acknowledgment. Keep the date and method on file.
- Staff and telehealth scripts. If prescribing happens by telehealth, check that intake flows and scripts match the updated form. See section 456.47, Florida Statutes.
- Pharmacy communication. Ask your compounding pharmacy whether it is changing any patient information it sends with the product, and keep that on file.
Signs your GLP-1 consent form may be out of date
- "We made this form in 2024 and have not touched it."
- "Our consent was copied from the manufacturer's brochure."
- "The form lists stomach and thyroid risks, but nothing about eyes."
- "Our staff say 'I'm not sure' when a patient asks about the news."
- "The medical director has not seen the form since we launched."
- "We use the same consent for every injectable."
- "Our exam notes are a checklist with no place for vision history."
What can happen if you get it wrong
If a patient reports vision loss and your records show no disclosure, the clinic may face a negligence or informed consent claim. Consent documentation is often the first thing reviewed.
Licensing boards can also ask what the clinic knew and when. A current form and a dated update show a clinic acting promptly.
Supervising physicians and nurse practitioners carry their own responsibilities. If supervision is part of your model, see our article on APRN Botox supervision in Florida for how those relationships work. Compounded products raise their own compliance questions, covered in our piece on the HHS peptide policy and Florida medspas.
No form prevents every claim. A well-kept record shows the patient was informed and the clinic acted responsibly.
How to fix it: a quick checklist
- Pull the FDA notice and save a copy in your compliance file.
- Send your current consent form, protocol, and exam template to your medical director for review.
- Add the vision warning and urgent-care instruction to the consent in plain language.
- Update intake questions on eye and vision history.
- Update exam note templates so vision history is documented.
- Decide how existing patients will be notified, and record when it happened.
- Train staff on one consistent answer to patient questions.
- Keep dated versions of every form so you can show what was in use and when.
- Schedule a recurring review so the next FDA or state change does not catch you off guard.
FAQ
Do compounded GLP-1s need the FDA vision warning?
The FDA label change applies to the drug labels. Compounded products have no label, so the warning will not appear on its own. A prudent clinic adds it to its consent and protocol, with its medical director's approval.
Is my old GLP-1 consent form still valid?
It may still be a signed record of what you disclosed at the time, but it does not cover the new warning. Ask your attorney and medical director whether existing patients should receive an update.
What is NAION?
NAION is nonarteritic anterior ischemic optic neuropathy, a sudden loss of vision caused by reduced blood flow to the optic nerve. Your medical director should explain the symptoms and the urgent-care instruction to patients.
Who has to approve the updated consent form?
Your medical director or supervising physician should approve the clinical content. An attorney should review the legal language and your record-keeping process.
Do I have to tell patients I already treated?
There is no single rule for every clinic. Have your attorney and medical director decide how to handle current patients, and document the decision.
Can I just use the manufacturer's patient information sheet?
Not safely on its own. It may not match your product, and it may not reflect your protocol. Use it as a reference, not as your consent.
Talk to a Florida health care business attorney
B&M Law Group, PLLC reviews GLP-1 and weight-loss program paperwork for clinics and medspas: consent forms, protocols, exam documentation, and medical director sign-off. We work in English and Spanish, throughout Florida.
If you want a second set of eyes on your forms before a patient asks about the news, book a consultation.
This article is for general information only and is not legal advice. Reading it does not create an attorney-client relationship. Please consult an attorney about your specific situation.
Sources: CNN: GLP-1 vision loss FDA warning · Rafferty Domnick Cunningham & Yaffa press release, GlobeNewswire · Fla. Stat. section 766.103 · Fla. Stat. section 458.348 · Fla. Stat. section 456.47